Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera<sup>®</sup>)

25 Nov 2013

Abstract excerpt

There has been great interest over the past two decades in developing gene therapies (GTs) to treat a variety of diseases; however, translating research findings into clinical treatments have proved to be a challenge. A major milestone in the development of GT has been achieved with the approval of alipogene tiparvovec (Glybera(®)) in Europe for the treatment of familial lipoprotein lipase deficiency. At this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24308784
DOI: 10.1586/17512433.2014.852065

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera<sup>®</sup>)PMID 24308784Read ↗

Immune Responses to AAV-Vectors, the Glybera Example from Bench to BedsideSemantic proximity Read ↗

Considerations for Preclinical Safety Assessment of Adeno-Associated Virus Gene Therapy ProductsSemantic proximity Read ↗

Infusion reactions to adeno‐associated virus (AAV)-based gene therapy: Mechanisms, diagnostics, treatment and review of the literatureSemantic proximity Read ↗

AAV vector manufacturing process design and scalability - Bending the trajectory to address vector-associated immunotoxicitiesSemantic proximity Read ↗

Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for HemophiliaSemantic proximity Read ↗

Gene Therapy in Lipoprotein Lipase Deficiency: Case Report on the First Patient Treated with Alipogene Tiparvovec Under Daily Practice ConditionsSemantic proximity Read ↗

Adeno-associated Vector Toxicity—To Be or Not to Be?Semantic proximity Read ↗

Scientific and Regulatory Policy Committee Points to Consider: Nonclinical Research and Development of In Vivo Gene Therapy Products, Emphasizing Adeno-Associated Virus VectorsSemantic proximity Read ↗

The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapySemantic proximity Read ↗

The Perspective of DMPK on Recombinant Adeno-Associated Virus-Based Gene Therapy: Past Learning, Current Support, and Future ContributionSemantic proximity Read ↗

Viral Vectors in Gene Replacement TherapySemantic proximity Read ↗

Manufacturing of recombinant adeno-associated viral vectors: new technologies are welcomeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.